AKT1 and osteosarcoma: In contrast, AIM2 might repress proliferation by inactivating the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway in osteosarcoma cells (170).